Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
GLP-1RAs have reliable hypoglycaemic and weight-loss effects that can intervene in obesitythe basis of type 2 diabetes pathologyand multifaceted effects on other cardiometabolic parameters, such as blood pressure and circulating lipids [21]
Kuhnil Biopharm Co., Ltd
It is a dual incretin medication that activates both GLP-1 and GIP receptors
GLP-1 and Diabetes Treatment 6
In a parallel matched cohort of 37,740 patients with both IBD and T2D, GLP-1 RA users had a 5-year colorectal cancer incidence of 0.31% vs 0.57% in non-users (OR, 0.54), representing a 46% reduction in odds
Moreover, increasing diagnosis and awareness of Type 2 diabetes are expected to provide the opportunity of expanding the market significantly
US$ 27.77
US$ 26.53
US$ 23.16
US$ 29.59
US$ 27.46
